

## **RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia**

TOKYO, July 2, 2026 - RIBOMIC, Inc. (TYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, announced today the enrollment of first patient (First Patient In, FPI) in the Phase 3 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in paediatric patients with achondroplasia (ACH).

This trial is a Phase 3 clinical trial in Japan targeting paediatric ACH patients (aged 2 to 14 years) and aims to evaluate the efficacy, safety, and pharmacokinetics of this drug. The design is to enroll 16 pediatric ACH patients and involve once-weekly subcutaneous administration of 1 mg/kg of umedaptanib pegol in a single-arm study without a placebo or active comparator. All subjects undergo a 26-week observation period prior to dosing initiation. The primary endpoint is the change in annualized height velocity (AHV) from baseline (the observation period) after 52 weeks of treatment.

There is no change to the full-year earnings forecast for the fiscal year ending March 2027 due to this matter.

### [About Umedaptanib Pegol]

Umedaptanib pegol is the international nonproprietary name (INN) for RBM-007. As an aptamer (nucleic acid medicine) that powerfully inhibits the function of fibroblast growth factor 2 (FGF2), it is expected to become a fundamental treatment directly targeting the pathogenesis of achondroplasia. This drug has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) of Japan.

### [About Achondroplasia]

Achondroplasia is a disease caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. This mutation makes FGFR3 more easily activated, leading to excessive influx of FGF signals. This inhibits the normal development of cartilage and other tissues, resulting in short stature accompanied by limb shortening. It is a rare disease with an incidence of approximately 1 in 25,000 newborns and is designated as an intractable disease.

The development of effective new drugs is urgently needed.

Please visit the RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

**Forward-Looking Statements** This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but are not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and News Release discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties. Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information: RIBOMIC Inc.  
[ir.inquiry@ribomic.com](mailto:ir.inquiry@ribomic.com)